Regenxbio Inc.
Most Recent
Why Arrowhead Pharmaceuticals Stock Rose Over 10% Yesterday
On December 12, Arrowhead Pharmaceuticals (ARWR) stock closed at $12.19, an ~11.53% rise from its previous day’s close of $13.62.
Arrowhead Pharmaceuticals Stock Has Risen ~252% Year-to-Date
On November 21, Arrowhead Pharmaceuticals (ARWR) stock closed at $12.95, a ~5.28% rise from its previous day’s close of $12.30.
Editas Stock: Analysts’ Recommendations
In November, among the ten analysts covering Editas Medicine (EDIT), six analysts recommended a “buy,” while four recommended a “hold.”
Audentes Therapeutics’ Promising Product Pipeline
In this series, we’ll take a look at six stocks with a focus on gene therapy that have promising products in their pipelines.
Analyzing Regenxbio’s Valuation Metrics
Regenxbio (RGNX) generated revenues of $40.03 million in the second quarter compared to $6.56 million in Q2 2017.
Are You Following Regenxbio in 2018?
Regenxbio (RGNX), a clinical stage biotechnology company, is exploring the curative potential of gene therapy.
How Analysts Rate Editas Medicine and Peers in August
Editas Medicine (EDIT) is a research-stage genome editing company. Five of the total nine analysts covering the company in August have given the stock a “buy” rating.
Netflix to Join S&P 100, Twitter to Join S&P 500, REGENEXBIO to Join S&P SmallCap 600
Netflix Inc. (NFLX), Twitter Inc. (TWTR), and REGENXBIO Inc. (RGNX) are up in pre-market trading on news that they will be added to certain S&P Dow Jones Indices. Here’s what you need to know.
How Regenxbio’s Cash Flows and Valuation Metrics Moved
Regenxbio (RGNX) spent $57.9 million in operating activities in fiscal 2017 compared to $48.5 million in fiscal 2016.